PDF(Pubmed)
Abstract：
Non-small cell lung cancer (NSCLC) is a significant global health issue with diverse molecular profiles affecting treatment responses. Yet, NSCLC\'s molecular epidemiology in Morocco is largely unexplored. This study focuses on NSCLC genetic mutations, specifically in adenocarcinoma, among Moroccan patients to contribute to understanding NSCLC in this population. Ninety-four patients diagnosed with lung adenocarcinoma were analyzed. Formalin-fixed paraffin-embedded tissue samples were processed, and deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) was extracted using standardized protocols. Mutations were detected using the AmoyDx Pan Lung Cancer Polymerase Chain Reaction (PCR) Panel kit, and their frequencies were assessed through statistical analysis. Epidermal Growth Factor Receptor (EGFR) mutations were detected in 22.34% of patients, predominantly exon 19 deletions (66.66%) and exon 21 L858R mutations (23.80%). Anaplastic lymphoma kinase (ALK) gene fusion was observed in 3.19% of patients, and KRAS mutations in 1.06%. No mutations were found in other tested genes. A slightly higher mutation rate was noted in females (54.16%) compared to males (45.84%). The study reveals a distinct mutation profile in Moroccan NSCLC patients, with a notable prevalence of EGFR mutations, albeit lower than in some Asian populations. The significance of EGFR mutations in treatment response aligns with global findings, highlighting the importance of understanding regional molecular variations for personalized therapy. Despite limitations in sample size and clinical data, this study sheds light on the genetic landscape of NSCLC in Morocco. The observed mutation rates, particularly in EGFR, underscore the potential for targeted therapies in Moroccan NSCLC patients, emphasizing the need for further research to refine treatment strategies tailored to this population.
摘要：
非小细胞肺癌（NSCLC）是一个重要的全球健康问题，具有影响治疗反应的不同分子谱。然而，在摩洛哥，NSCLC的分子流行病学在很大程度上尚未被探索。本研究集中于NSCLC基因突变，特别是在腺癌中，摩洛哥患者有助于了解该人群中的非小细胞肺癌。分析94例诊断为肺腺癌的患者。处理福尔马林固定石蜡包埋的组织样品，使用标准化方案提取脱氧核糖核酸（DNA）/核糖核酸（RNA）。使用AmoyDxPan肺癌聚合酶链反应（PCR）面板试剂盒检测突变，并通过统计分析评估其频率。在22.34％的患者中检测到表皮生长因子受体（EGFR）突变，主要是外显子19缺失(66.66%)和外显子21L858R突变(23.80%)。间变性淋巴瘤激酶(ALK)基因融合者占3.19%,而KRAS基因突变率为1.06%。在其他测试基因中未发现突变。与男性（45.84％）相比，女性（54.16％）的突变率略高。该研究揭示了摩洛哥NSCLC患者的独特突变特征，EGFR突变的明显流行，尽管低于一些亚洲人口。EGFR突变在治疗反应中的意义与全球发现一致，强调了解区域分子变异对个性化治疗的重要性。尽管样本量和临床数据有限，这项研究揭示了摩洛哥非小细胞肺癌的遗传前景。观察到的突变率，特别是在EGFR中，强调了摩洛哥非小细胞肺癌患者靶向治疗的潜力，强调需要进一步研究以完善针对该人群的治疗策略。
